Evidence map›Paper›PMID 38071661›Full record

Trial reportAnnals of medicine2023

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.

Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Hong Zhang, Cuiyun Li, Yanhua Ding

Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jia XuPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Hong ZhangPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Hong ChenPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Xiaoxue ZhuPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Haiyan JiaPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Zhongnan XuChia Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, China.
Dandan HuoChia Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, China.
Hong ZhangChia Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, China.
Cuiyun LiPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Yanhua DingPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Non-alcoholic Fatty Liver DiseaseArea Under CurveBile Acids and SaltsChinaDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHumansBile Acids and Saltsfood effectpharmacodynamicspharmacokineticssafetytolerabilityTQA3526

Identifiers

PMID38071661
PMCPMC10836247
OpenAlexW4389521257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.